Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of metformin in preparation of medicine for treating eye melanoma

A technology for metformin and melanoma, which is used in antitumor drugs, drug combinations, pharmaceutical formulations, etc.

Pending Publication Date: 2021-09-10
SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report on the relationship between metformin and ocular melanoma disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of metformin in preparation of medicine for treating eye melanoma
  • Application of metformin in preparation of medicine for treating eye melanoma
  • Application of metformin in preparation of medicine for treating eye melanoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1I

[0020] Embodiment 1 IC50 determination experiment

[0021] Experimental materials: human uveal melanoma cell lines MUM2B, MEL290, human conjunctival melanoma cell lines CRMM1, CM2005.1, human normal melanocyte PIG1, human retinal pigment epithelial cell ARPE-19. Metformin (Metformin) was purchased from Selleck (China), and CCK8 was purchased from Tongren Chemical (Japan).

[0022] Experimental steps: (1) MUM2B, MEL290, CRMM1, CM2005.1, PIG1, ARPE-19 cells were routinely cultured in a 37°C, 5% CO2 incubator. MUM2B, MEL290, and ARPE-19 were cultured in DMEM with 10% FBS, and CRMM1, CM2005.1, and PIG1 were cultured in F12-K with 10% FBS.

[0023] (2) The cells were cultured to a density of 70%-80%. When the refractive index was high, they were digested with trypsin, centrifuged at 800rpm for 4min, the supernatant was removed, and resuspended with 2ml of complete medium. Pipette evenly, take 20 μl and count with a cell counting plate, inoculate 3000 cells per well in a 384-well ...

Embodiment 2

[0025] Example 2 Plate colony formation experiment

[0026] Experimental materials: human uveal melanoma cell lines MUM2B, MEL290, human conjunctival melanoma cell lines CRMM1, CM2005.1, human normal melanocyte PIG1. Metformin (Metformin) was purchased from Selleck (China), pancreatin was purchased from Xinsaimei Biotech (China), 4% paraformaldehyde and crystal violet dye were purchased from Shenggong Company (China).

[0027] Experimental steps: (1) MUM2B, MEL290, CRMM1, CM2005.1, and PIG1 cells were conventionally cultured in a 5% CO2 incubator at 37°C. MUM2B and MEL290 were cultured in DMEM with 10% FBS, and CRMM1, CM2005.1 and PIG1 were cultured in F12-K with 10% FBS.

[0028] (2) The cells were cultured to a density of 70%-80%. When the refractive index was high, they were digested with trypsin, centrifuged at 800rpm for 4min, the supernatant was removed, and resuspended with 2ml of complete medium. Pipette evenly, take 20 μl and count with a cell counting plate, take 1...

Embodiment 3

[0030] Example 3 Transwell cell migration experiment

[0031]Experimental materials: human uveal melanoma cell lines MUM2B, MEL290, human conjunctival melanoma cell line CRMM1. Metformin was purchased from Selleck (China), 24-well plates were purchased from Thermo Fisher (USA), and 24-well plate Transwell chambers were purchased from Millipore (USA).

[0032] Experimental steps: (1) MUM2B, MEL290, CRMM1, CM2005.1, and PIG1 cells were conventionally cultured in a 5% CO2 incubator at 37°C. MUM2B and MEL290 were cultured in DMEM with 10% FBS, and CRMM1, CM2005.1 and PIG1 were cultured in F12-K with 10% FBS.

[0033] (2) The cells were cultured to a density of 70%-80%. When the refractive index was high, they were digested with trypsin, centrifuged at 800rpm for 4min, the supernatant was removed, and resuspended with 2ml of complete medium. Pipette evenly, take 20 μl and count with a cell counting plate. Add 900 μl of 10% FBS medium to each well of a 24-well plate, hang 8 μm Tr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention finds that metformin can obviously inhibit the growth of eye melanoma cells, and the drug action effect is increased along with the increase of the concentration. The invention aims at providing a new clinical treatment medicine for the eye melanoma, improving the treatment effectiveness, prolonging the life of a patient and improving the life quality, so that a new field of applying the metformin to the treatment of the eye melanoma is developed.

Description

technical field [0001] The invention relates to the technical field of eye melanoma treatment, in particular to the application of metformin in the preparation of medicine for treating eye melanoma. Background technique [0002] Ocular melanoma includes uveal melanoma (Uveal melanoma, UM) and conjunctival melanoma (Conjunctival melanoma, CM). Among them, UM is the most common intraocular malignancy in adults, with a high degree of malignancy. About 50% of UM patients develop liver metastases, and the median survival time of patients with liver metastases is only 10.2 months. The onset of CM is relatively insidious, and often does not affect vision in the early stage. When it is found, it often spreads and metastasizes, and the prognosis is poor, which seriously affects the life and health of patients. At present, the main treatment methods for ocular melanoma are surgery and radiotherapy and chemotherapy, but it is not sensitive to conventional radiotherapy and chemotherapy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/155A61P27/02A61P35/00
CPCA61K31/155A61P27/02A61P35/00A61P35/04
Inventor 庄艾范先群柴佩韦王少云
Owner SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com